Company research
Mural Oncology plc
CIK 1971543Updated Sep 26, 2026
Securities
Historical securities (2)
MURA · OTC · equity · closed Dec 4, 2025MURAV · OTC · equity · closed Nov 15, 2023Name history
Mural Oncology Ltd · through Aug 24, 2023
MURA price & chart
Historical security
This listing closed Dec 4, 2025. Live provider charts are shown only for current listings.
About the company
Mural Oncology plc is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. On March 25, 2025, Mural announced that, based on the interim analysis of results, its Phase 3 ARTISTRY-7 trial of nemvaleukin alfa (“nemvaleukin”) in combination with pembrolizumab did not achieve its primary endpoint of a statistically significant improvement in overall survival versus investigator’s choice chemotherapy. Mural also announced that ARTISTRY-7 would not continue to final analysis and Mural would cease development of nemvaleukin for platinum resistant ovarian cancer. On April 15, 2025, Mural announced that following review of data from its Phase 2 ARTISTRY-6 trial of nemvaleukin in mucosal and cutaneous melanoma and the previously announced results from the ARTISTRY-7 trial, Mural was discontinuing all clinical development of nemvaleukin and planned to immediately commence an exploration of strategic alternatives focused on maximizing shareholder value.
In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 169,394,000Source | 301,745,000Source | 33,750,000Source |
| Property, Plant and Equipment, NetUSD | 7,715,000Source | 11,403,000Source | 10,617,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 115,462,000Source | 270,852,000Source | 0Source |
| Assets, CurrentUSD | 152,917,000Source | 277,337,000Source | 4,817,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,783,000Source | 12,747,000Source | 18,316,000Source |
| Other Assets, NoncurrentUSD | 10,000Source | — | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 28,892,000Source | 37,928,000Source | 55,406,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 171,000Source | 167,000Source | 0Source |
| Additional Paid in CapitalUSD | 299,682,000Source | 294,507,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -159,371,000Source | -30,857,000Source | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 140,502,000Source | 263,817,000Source | -21,656,000Source |
| Liabilities and EquityUSD | 169,394,000Source | 301,745,000Source | 33,750,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 26,195,000Source | 29,017,000Source | 41,560,000Source |
| Operating Lease, Liability, CurrentUSD | 5,560,000Source | 6,098,000Source | 5,844,000Source |
| Accounts Payable, CurrentUSD | 2,056,000Source | 5,973,000Source | 2,966,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,462,000Source | 8,911,000Source | 13,542,000Source |
| Other Liabilities, NoncurrentUSD | 235,000Source | 0Source | 304,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 18,534,000Source | 16,946,000Source | 32,750,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -128,514,000Source | -207,447,000Source | -189,807,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,081,000Source | 24,109,000Source | 11,931,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -128,545,000Source | -194,249,000Source | -168,588,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -25,330,000Source | -3,452,000Source | -5,511,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 92,000Source | 3,452,000Source | 5,511,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 196,000Source | 468,811,000Source | 174,099,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -153,679,000Source | 271,110,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 117,431,000Source | 271,110,000Source | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 5,081,000Source | 24,109,000Source | 11,931,000Source |
| DepreciationUSD | 3,512,000Source | 2,567,000Source | 1,540,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -96,000Source | — | — |
| General and Administrative ExpenseUSD | 27,596,000Source | 30,706,000Source | 17,732,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 12,160,000Source | 4,884,000Source |
| Net Income (Loss) Attributable to ParentUSD | -128,514,000Source | -207,447,000Source | -189,807,000Source |
| Operating ExpensesUSD | 138,262,000Source | 196,238,000Source | 184,923,000Source |
| Other Nonoperating Income (Expense)USD | 9,748,000Source | 951,000Source | — |
| Other Operating Income (Expense), NetUSD | 9,748,000Source | — | — |
| Proceeds from Contributions from ParentUSD | — | 468,811,000Source | 174,099,000Source |
| Proceeds from Issuance of Common StockUSD | 196,000Source | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Operating Income (Loss)USD | -138,262,000Source | -196,238,000Source | -184,923,000Source |
| Other Nonoperating Income (Expense)USD | 9,748,000Source | 951,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -128,514,000Source | -195,287,000Source | -184,923,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 12,160,000Source | 4,884,000Source |
| Net Income (Loss) Attributable to ParentUSD | -128,514,000Source | -207,447,000Source | -189,807,000Source |
| Earnings Per Share, BasicUSD per share | -7.58Source | -12.43Source | -11.37Source |
| Earnings Per Share, DilutedUSD per share | -7.58Source | -12.43Source | -11.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,954,577Source | 16,689,740Source | 16,689,740Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,954,577Source | 16,689,740Source | 16,689,740Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 27,596,000Source | 30,706,000Source | 17,732,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -127,521,000Source | -8,115,000Source | -6,230,000Source |
| Operating ExpensesUSD | 138,262,000Source | 196,238,000Source | 184,923,000Source |
| Other Operating Income (Expense), NetUSD | 9,748,000Source | — | — |
| Research and Development ExpenseUSD | 110,666,000Source | 165,532,000Source | 167,191,000Source |